Goldman Sachs’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $7.99M | Buy |
17,900
+2,500
| +16% | +$1.17M | ﹤0.01% | 3251 |
|
|
2025
Q4 | $6.98M | Sell |
15,400
-21,500
| -58% | -$9.27M | ﹤0.01% | 3439 |
|
|
2025
Q3 | $14.5M | Buy |
36,900
+19,200
| +108% | +$8.02M | ﹤0.01% | 2594 |
|
|
2025
Q2 | $7.88M | Buy |
17,700
+8,300
| +88% | +$3.82M | ﹤0.01% | 2973 |
|
|
2025
Q1 | $4.56M | Buy |
9,400
+2,900
| +45% | +$1.35M | ﹤0.01% | 3455 |
|
|
2024
Q4 | $2.62M | Sell |
6,500
-3,000
| -32% | -$1.39M | ﹤0.01% | 4056 |
|
|
2024
Q3 | $4.42M | Sell |
9,500
-100
| -1% | -$48K | ﹤0.01% | 3456 |
|
|
2024
Q2 | $4.5M | Sell |
9,600
-24,300
| -72% | -$10.5M | ﹤0.01% | 3245 |
|
|
2024
Q1 | $14.2M | Buy |
33,900
+4,200
| +14% | +$1.78M | ﹤0.01% | 2147 |
|
|
2023
Q4 | $12.1M | Sell |
29,700
-4,200
| -12% | -$1.55M | ﹤0.01% | 2356 |
|
|
2023
Q3 | $11.8M | Sell |
33,900
-19,300
| -36% | -$6.75M | ﹤0.01% | 2258 |
|
|
2023
Q2 | $18.7M | Sell |
53,200
-55,500
| -51% | -$18.7M | ﹤0.01% | 1909 |
|
|
2023
Q1 | $34.2M | Buy |
108,700
+15,300
| +16% | +$4.59M | 0.01% | 1345 |
|
|
2022
Q4 | $27M | Buy |
93,400
+55,200
| +145% | +$16.8M | 0.01% | 1692 |
|
|
2022
Q3 | $11.1M | Buy |
+38,200
| New | +$11M | ﹤0.01% | 2416 |
|
|
2022
Q2 | – | Sell |
-35,100
| Closed | -$9.16M | – | 6747 |
|
|
2022
Q1 | $9.16M | Sell |
35,100
-10,800
| -24% | -$2.56M | ﹤0.01% | 2779 |
|
|
2021
Q4 | $10.1M | Buy |
45,900
+30,900
| +206% | +$6.01M | ﹤0.01% | 2754 |
|
|
2021
Q3 | $2.72M | Sell |
15,000
-86,900
| -85% | -$17M | ﹤0.01% | 3908 |
|
|
2021
Q2 | $20.5M | Sell |
101,900
-175,200
| -63% | -$36.6M | ﹤0.01% | 2029 |
|
|
2021
Q1 | $59.5M | Buy |
277,100
+269,500
| +3,546% | +$59.2M | 0.02% | 1032 |
|
|
2020
Q4 | $1.8M | Sell |
7,600
-12,400
| -62% | -$2.85M | ﹤0.01% | 3812 |
|
|
2020
Q3 | $5.44M | Buy |
+20,000
| New | +$5.52M | ﹤0.01% | 2825 |
|
|
2020
Q2 | – | Sell |
-30,500
| Closed | -$7.26M | – | 5505 |
|
|
2020
Q1 | $7.26M | Buy |
+30,500
| New | +$7M | ﹤0.01% | 2337 |
|
|
2019
Q4 | – | Sell |
-19,700
| Closed | -$3.34M | – | 5420 |
|
|
2019
Q3 | $3.34M | Sell |
19,700
-49,900
| -72% | -$8.83M | ﹤0.01% | 3153 |
|
|
2019
Q2 | $12.8M | Buy |
+69,600
| New | +$12.2M | ﹤0.01% | 2195 |
|
|
2019
Q1 | – | Sell |
-2,000
| Closed | -$331K | – | 5471 |
|
|
2018
Q4 | $331K | Buy |
+2,000
| New | +$347K | ﹤0.01% | 4586 |
|
|
2018
Q3 | – | Sell |
-30,100
| Closed | -$5.12M | – | 5803 |
|
|
2018
Q2 | $5.12M | Sell |
30,100
-49,200
| -62% | -$7.63M | ﹤0.01% | 2949 |
|
|
2018
Q1 | $12.9M | Buy |
79,300
+28,200
| +55% | +$4.61M | ﹤0.01% | 2148 |
|
|
2017
Q4 | $7.66M | Sell |
51,100
-61,900
| -55% | -$9.17M | ﹤0.01% | 2662 |
|
|
2017
Q3 | $17.2M | Buy |
113,000
+69,300
| +159% | +$10.4M | ﹤0.01% | 2123 |
|
|
2017
Q2 | $5.63M | Sell |
43,700
-350,800
| -89% | -$42.2M | ﹤0.01% | 2957 |
|
|
2017
Q1 | $43.1M | Buy |
394,500
+292,200
| +286% | +$25.7M | 0.01% | 1320 |
|
|
2016
Q4 | $7.54M | Buy |
102,300
+70,000
| +217% | +$5.7M | ﹤0.01% | 2686 |
|
|
2016
Q3 | $2.82M | Buy |
32,300
+18,700
| +138% | +$1.77M | ﹤0.01% | 3530 |
|
|
2016
Q2 | $1.17M | Sell |
13,600
-5,000
| -27% | -$432K | ﹤0.01% | 4062 |
|
|
2016
Q1 | $1.48M | Buy |
18,600
+3,700
| +25% | +$335K | ﹤0.01% | 3745 |
|
|
2015
Q4 | $1.88M | Sell |
14,900
-12,700
| -46% | -$1.53M | ﹤0.01% | 3689 |
|
|
2015
Q3 | $2.87M | Sell |
27,600
-1,400
| -5% | -$180K | ﹤0.01% | 3414 |
|
|
2015
Q2 | $3.58M | Sell |
29,000
-4,400
| -13% | -$554K | ﹤0.01% | 3261 |
|
|
2015
Q1 | $3.94M | Sell |
33,400
-93,800
| -74% | -$11.2M | ﹤0.01% | 3124 |
|
|
2014
Q4 | $15.1M | Buy |
127,200
+37,400
| +42% | +$4.21M | ﹤0.01% | 2021 |
|
|
2014
Q3 | $10.1M | Sell |
89,800
-664,800
| -88% | -$63.3M | ﹤0.01% | 2360 |
|
|
2014
Q2 | $71.4M | Buy |
754,600
+309,500
| +70% | +$21.7M | 0.02% | 872 |
|
|
2014
Q1 | $31.5M | Buy |
445,100
+373,800
| +524% | +$29.6M | 0.01% | 1397 |
|
|
2013
Q4 | $5.3M | Sell |
71,300
-158,100
| -69% | -$11M | ﹤0.01% | 3020 |
|
|
2013
Q3 | $17.4M | Sell |
229,400
-68,700
| -23% | -$5.47M | 0.01% | 1747 |
|
|
2013
Q2 | $23.9M | Buy |
+298,100
| New | +$22M | 0.01% | 1404 |
|
Other funds holding VRTX
VCM
VPM
Goldman Sachs's VRTX Position: Q1 2026 in Review
Goldman Sachs increased its Vertex Pharmaceuticals (VRTX) stake by 38% in Q1 2026, buying an estimated $310M and bringing the position to 2,417,875 shares worth $1.08B. The position accounts for 0.12% of the portfolio, ranked #152.
Goldman Sachs first reported a position in VRTX in Q2 2013 and has held it in 52 quarters since. 1,688 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.
- Goldman Sachs held 2,417,875 shares of Vertex Pharmaceuticals worth $1.08B as of Q1 2026.
- Goldman Sachs bought 663,757 Vertex Pharmaceuticals shares in Q1 2026, an estimated $310M.
- Vertex Pharmaceuticals made up 0.12% of Goldman Sachs's portfolio in Q1 2026, its #152 holding.
- Goldman Sachs first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
- 1,688 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.
Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.